Cargando…

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection

Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4–infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Nannan, Hernandez, Dennis, Ueland, Joseph, Yang, Xiaoyan, Yu, Fei, Sims, Karen, Yin, Philip D., McPhee, Fiona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690147/ https://www.ncbi.nlm.nih.gov/pubmed/26170396 http://dx.doi.org/10.1093/infdis/jiv379

Ejemplares similares

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir
por: Friborg, Jacques, et al.
Publicado: (2014)

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
por: McPhee, Fiona, et al.
Publicado: (2015)

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir
por: Safadi, Rifaat, et al.
Publicado: (2016)

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study
por: Flower, Barnaby, et al.
Publicado: (2021)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2020)

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
por: Rose, Ronald E., et al.
Publicado: (2018)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Corrigendum: A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2021)

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
por: Leroy, Vincent, et al.
Publicado: (2016)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
por: Foster, Graham R., et al.
Publicado: (2016)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors
por: De Luca, Andrea, et al.
Publicado: (2015)

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
por: Nelson, David R, et al.
Publicado: (2015)

Daclatasvir: potential role in hepatitis C
por: Lee, Choongho
Publicado: (2013)

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
por: Bartolini, Barbara, et al.
Publicado: (2017)

Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1
por: Ide, Tatsuya, et al.
Publicado: (2016)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Daclatasvir: potential role in hepatitis C [Corrigendum]
Publicado: (2014)

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
por: Gamal, Nesrine, et al.
Publicado: (2016)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019)

Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt
por: Elsadek Fakhr, Ahmed, et al.
Publicado: (2013)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice
por: Lee, Seung-Hoon, et al.
Publicado: (2018)

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
por: Manolakopoulos, Spilios, et al.
Publicado: (2016)

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017)

Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV–Hepatitis C Virus Coinfection
por: Moqueet, Nasheed, et al.
Publicado: (2016)

Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
por: Nettles, James H., et al.
Publicado: (2014)

Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
por: Schwarz, Tino F, et al.
Publicado: (2019)

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
por: Lu, Yun, et al.
Publicado: (2018)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies
por: Verstrepen, Babs E., et al.
Publicado: (2011)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0nrtueo0i1t76mm5sh80qbo83k